Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep 19;105(19):1441–1456. doi: 10.1093/jnci/djt209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2013. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Preclinical studies in patient-derived human tumor xenograft (PDTX) models correctly predict lack of response to epidermal growth factor receptor (EGFR) antibodies in KRAS-mutant colorectal cancer (CRC). Results from a retrospective analysis evaluating the effect of KRAS mutational status on overall survival in patients treated with cetuximab (A, B) and results from a PDTX trial evaluating the effect of KRAS mutational status on overall survival in PDTX patients treated with cetuximab (C, D) (24). KRAS-mutant PDTX patients treated with cetuximab had similar survival curves compared with control (CTRL) PDTX patients (C). KRAS wild-type PDTX patients treated with cetuximab had statistically significantly improved survival compared with control PDTX patients (D). The results from the xenopatient trial mirror the results seen clinically, suggesting that the lack of efficacy of EGFR monoclonal antibodies in KRAS-mutant CRC could have been predicted preclinically (34). Reprinted with permission from the New England Journal of Medicine and the American Association for Cancer Research.